Lemaitre Vasculr SEC Filings

LeMaitre Vascular (LMAT) Form 4: Director Martha Shadan reported acquisitions of dividend equivalent rights on 09/04/2025 that accrued on prior equity awards. The filing lists five separate accrual entries tied to restricted stock units and performance share units granted on 12/12/2022, 12/8/2023 and 12/6/2024. Each entry shows fractional amounts of economic share equivalents acquired (0.4173; 0.4173; 0.7138; 0.8546; 0.8697) at a reported price of $0, with ownership reported as Direct (D). The Form is signed by Nathan Ulrich on 09/08/2025.

LeMaitre Vascular director John A. Roush received multiple dividend equivalent rights tied to prior equity awards that vest proportionately with those awards. The Form 4 reports acquisitions on 09/04/2025 of dividend equivalent rights that are the economic equivalent of common stock: 0.4173, 0.4173, 0.7138, 0.8546 and 0.8697 shares, each recorded as acquired at $0 price and held directly. Each set of rights accrued on RSU or PSU awards granted in 2022, 2023 and 2024 and will vest in line with those underlying awards, converting economically into common stock when vested.

LeMaitre Vascular, Inc. (LMAT) director Bridget A. Ross reported the acquisition of dividend equivalent rights tied to prior equity awards. On 09/04/2025 Ms. Ross was credited with five separate accruals of dividend equivalent rights that are the economic equivalent of common shares. The accruals total individual amounts of 0.4173, 0.4173, 0.7138, 0.8546, and 0.8697 units and are linked to restricted stock unit and performance share unit awards granted on 12/12/2022, 12/08/2023, and 12/06/2024. Each accrual vests proportionately with the underlying award and carries a reported price of $0 per right. The Form 4 was signed on 09/08/2025.

LeMaitre Vascular director John James O'Connor reported changes in beneficial ownership on Form 4 relating to dividend equivalent rights that accrued on previously granted equity awards. The filing shows transactions dated 09/04/2025 recording a series of small accruals of dividend equivalent rights tied to restricted stock units and performance share unit awards granted on 12/12/2022, 12/8/2023 and 12/6/2024. Each dividend equivalent right is described as the economic equivalent of one share of the issuer's common stock. The filing was signed by Nathan Ulrich on 09/08/2025. The report indicates the form was filed by one reporting person who is a director of the issuer (LMAT).

Lawrence J. Jasinski, a director of LeMaitre Vascular, Inc. (LMAT), reported on Form 4 that on 09/04/2025 he received dividend equivalent rights tied to previously granted equity awards. The Form 4 lists five separate accruals of dividend equivalent rights that arose from restricted stock unit and performance stock unit awards granted on 12/12/2022, 12/8/2023 and 12/6/2024. Each dividend equivalent right is described as the economic equivalent of one share of common stock and vests proportionately with the underlying award. The filing shows fractional share amounts for each accrual and the number of shares beneficially owned following the transactions. The Form 4 was signed by Nathan Ulrich on 09/08/2025.

LeMaitre Vascular insider report: This Form 4, filed for Trent G. Kamke (Senior V.P., Operations), discloses accrual and acquisition of dividend equivalent rights tied to restricted stock unit (RSU) and performance share unit (PSU) awards that vest proportionately. Transactions are dated 09/04/2025. The report lists multiple accruals that convert economically to common shares, with individual tranche amounts shown (examples: 0.3386, 0.6173, 1.2562, 1.6108, 1.9307, 1.9194). No cash consideration is reported and ownership form is direct. The filing documents routine compensation-related accruals rather than open-market purchases or sales.

LeMaitre Vascular Inc. (LMAT) Form 4: Dorian Paul LeBlanc, identified as Chief Financial Officer and a director, reported a transaction dated 09/04/2025. The filing records the acquisition of dividend equivalent rights that accrued on a restricted stock unit award originally granted on 03/10/2025. Each dividend equivalent right is the economic equivalent of one share of the company’s common stock. The report shows an acquisition at $0 and a post-transaction beneficial ownership figure of 8.4578 (direct). The form is signed on the filing by Nathan Ulrich on 09/08/2025.

LeMaitre Vascular, Inc. (LMAT) reporting person Joseph P. Pellegrino Jr., a company director, reported accruals of dividend equivalent rights on 09/04/2025 tied to previously granted restricted stock unit (RSU) and performance share unit (PSU) awards. The filing itemizes seven separate dividend-equivalent accruals that vest proportionately with their underlying awards, referencing grant dates from 12/2/2020 through 12/6/2024. The report shows the reporting person acquired 19.0048 dividend equivalent rights on 09/04/2025, which correspond to 176.2176 shares of common stock economic equivalent following the transactions. The entries are non-cash accruals (price listed as $0) and were certified by signature on 09/08/2025.

David B. Roberts, serving as President and Director of LeMaitre Vascular, acquired a series of dividend equivalent rights tied to previously granted restricted stock units and performance share units. The rights, recorded on 09/04/2025, represent the economic equivalent of shares of the issuer's common stock and arise from awards dated 12/2/2020, 12/11/2021, 12/12/2022, 12/8/2023, 12/6/2024 and 2/18/2025. The reported increments of dividend equivalent rights total 18.5799 share-equivalents across eight award lines, each showing zero purchase price and classified as direct ownership. The table lists the post-transaction beneficially owned share-equivalents for each line, indicating modest accruals that vest proportionately with the underlying awards.